tirzepatide discontinuation Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 tirzepatide discontinuation Changes in weight

Diabetic vascular complications often coexist with autonomic neuropathy, disrupting local vascular regulation in the testes

These effects may relate to fluctuating glucose levels and mild dehydration from appetite suppression

There are discussions about using these drugs in overweight individuals (BMI 2730) to prevent progression to obesity or to treat weight-related conditions even at lower BMI, but currently insurance coverage is mainly for obesity or diabetes

Jumping directly to a higher dose can cause severe nausea, vomiting, and discomfort

Some people wonder whether this could lead to unexpected bleeding

FSSAI certified, NABL tested